{
    "organizations": [],
    "uuid": "c7e4be27b7cb6e53a788cf4b3d83bb9003533339",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/06/pr-newswire-valeant-will-release-fourth-quarter-and-full-year-2017-financial-results-on-february-28.html",
    "ord_in_thread": 0,
    "title": "Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "LAVAL, Quebec, Feb. 6, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (\"Valeant\") will release its fourth-quarter and full-year 2017 financial results on Wednesday, Feb. 28, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.\nConference Call Details\nDate:\nWednesday, Feb. 28, 2018\nTime:\n8:00 a.m. EST\nWebcast:\nhttp://ir.valeant.com/events-and-presentations\nParticipant Event Dial-in:\n(844) 428-3520 (North America)\n(409) 767-8386 (International)\nParticipant Passcode:\n5287247\nReplay Dial-in:\n(855) 859-2056 (North America)\n(404) 537-3406 (International)\nReplay Passcode:\n5287247 (replay available until Apr. 28, 2018)\nAbout Valeant\nValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com .\nInvestor Contact:\nMedia Contact:\nArthur Shannon\nLainie Keller\narthur.shannon@valeant.com\nlainie.keller@valeant.com\n(514) 856-3855\n(908) 927-0617\n(877) 281-6642 (toll free)\nView original content with multimedia: http://www.prnewswire.com/news-releases/valeant-will-release-fourth-quarter-and-full-year-2017-financial-results-on-february-28-300594219.html\nSOURCE Valeant Pharmaceuticals International, Inc.",
    "published": "2018-02-06T18:25:00.000+02:00",
    "crawled": "2018-02-06T18:50:41.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "laval",
        "quebec",
        "valeant",
        "pharmaceutical",
        "international",
        "nyse",
        "vrx",
        "tsx",
        "vrx",
        "valeant",
        "release",
        "financial",
        "result",
        "wednesday",
        "valeant",
        "host",
        "conference",
        "call",
        "live",
        "web",
        "cast",
        "est",
        "discus",
        "result",
        "provide",
        "business",
        "update",
        "material",
        "made",
        "available",
        "investor",
        "relation",
        "section",
        "valeant",
        "web",
        "site",
        "prior",
        "start",
        "call",
        "conference",
        "call",
        "detail",
        "date",
        "wednesday",
        "time",
        "est",
        "webcast",
        "http",
        "participant",
        "event",
        "north",
        "america",
        "international",
        "participant",
        "passcode",
        "replay",
        "north",
        "america",
        "international",
        "replay",
        "passcode",
        "replay",
        "available",
        "apr",
        "valeant",
        "valeant",
        "pharmaceutical",
        "international",
        "vrx",
        "multinational",
        "specialty",
        "pharmaceutical",
        "company",
        "develops",
        "manufacture",
        "market",
        "broad",
        "range",
        "pharmaceutical",
        "product",
        "primarily",
        "area",
        "dermatology",
        "gastrointestinal",
        "disorder",
        "eye",
        "health",
        "neurology",
        "branded",
        "generic",
        "information",
        "valeant",
        "found",
        "investor",
        "contact",
        "medium",
        "contact",
        "arthur",
        "shannon",
        "lainie",
        "keller",
        "toll",
        "free",
        "view",
        "original",
        "content",
        "multimedia",
        "http",
        "source",
        "valeant",
        "pharmaceutical",
        "international",
        "inc"
    ]
}